Dong-A Socio Holdings Co., Ltd. (000640.KS)
KRW 110000.0
(4.86%)
KRW 110000.0
(4.86%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 572.02 Billion KRW | 25.17% |
| 2022 | 457 Billion KRW | 4.35% |
| 2021 | 437.94 Billion KRW | 9.73% |
| 2020 | 399.11 Billion KRW | 4.57% |
| 2019 | 381.68 Billion KRW | 44.92% |
| 2018 | 263.37 Billion KRW | 20.25% |
| 2017 | 219.01 Billion KRW | -17.46% |
| 2016 | 265.35 Billion KRW | -14.34% |
| 2015 | 309.77 Billion KRW | 30.81% |
| 2014 | 236.81 Billion KRW | 144.1% |
| 2013 | 97.01 Billion KRW | -3.94% |
| 2012 | 100.99 Billion KRW | -12.92% |
| 2011 | 115.98 Billion KRW | -0.9% |
| 2010 | 117.03 Billion KRW | -48.62% |
| 2009 | 227.79 Billion KRW | 2.29% |
| 2008 | 222.7 Billion KRW | 30.7% |
| 2007 | 170.39 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 585.48 Billion KRW | 4.25% |
| 2024 Q1 | 561.64 Billion KRW | -1.81% |
| 2023 FY | 572.02 Billion KRW | 25.17% |
| 2023 Q2 | 489.6 Billion KRW | 1.4% |
| 2023 Q1 | 482.83 Billion KRW | 5.65% |
| 2023 Q3 | 545.07 Billion KRW | 11.33% |
| 2023 Q4 | 572.02 Billion KRW | 4.94% |
| 2022 Q4 | 457 Billion KRW | 3.12% |
| 2022 FY | 457 Billion KRW | 4.35% |
| 2022 Q3 | 443.19 Billion KRW | 3.17% |
| 2022 Q2 | 429.58 Billion KRW | -0.86% |
| 2022 Q1 | 433.3 Billion KRW | -1.06% |
| 2021 Q4 | 437.94 Billion KRW | 7.56% |
| 2021 FY | 437.94 Billion KRW | 9.73% |
| 2021 Q3 | 407.15 Billion KRW | 1.98% |
| 2021 Q2 | 399.23 Billion KRW | -2.53% |
| 2021 Q1 | 409.58 Billion KRW | 2.62% |
| 2020 Q3 | 400.18 Billion KRW | -5.35% |
| 2020 Q1 | 388.32 Billion KRW | 1.74% |
| 2020 Q2 | 422.81 Billion KRW | 8.88% |
| 2020 Q4 | 399.11 Billion KRW | -0.27% |
| 2020 FY | 399.11 Billion KRW | 4.57% |
| 2019 Q3 | 265.23 Billion KRW | -11.89% |
| 2019 Q4 | 381.68 Billion KRW | 43.91% |
| 2019 Q2 | 301.04 Billion KRW | 4.23% |
| 2019 Q1 | 288.83 Billion KRW | 9.66% |
| 2019 FY | 381.68 Billion KRW | 44.92% |
| 2018 Q4 | 263.37 Billion KRW | 20.45% |
| 2018 FY | 263.37 Billion KRW | 20.25% |
| 2018 Q2 | 209.78 Billion KRW | -7.32% |
| 2018 Q1 | 226.35 Billion KRW | 3.35% |
| 2018 Q3 | 218.66 Billion KRW | 4.24% |
| 2017 Q4 | 219.01 Billion KRW | 5.3% |
| 2017 Q3 | 207.98 Billion KRW | -7.24% |
| 2017 Q2 | 224.21 Billion KRW | -3.16% |
| 2017 FY | 219.01 Billion KRW | -17.46% |
| 2017 Q1 | 231.53 Billion KRW | -12.75% |
| 2016 FY | 265.35 Billion KRW | -14.34% |
| 2016 Q2 | 266.57 Billion KRW | -15.36% |
| 2016 Q3 | 260.28 Billion KRW | -2.36% |
| 2016 Q4 | 265.35 Billion KRW | 1.95% |
| 2016 Q1 | 314.94 Billion KRW | 1.67% |
| 2015 Q4 | 309.77 Billion KRW | 11.78% |
| 2015 Q3 | 277.14 Billion KRW | -6.24% |
| 2015 FY | 309.77 Billion KRW | 30.81% |
| 2015 Q1 | 275.56 Billion KRW | 16.36% |
| 2015 Q2 | 295.59 Billion KRW | 7.27% |
| 2014 Q3 | 195.04 Billion KRW | 16.86% |
| 2014 FY | 236.81 Billion KRW | 144.1% |
| 2014 Q4 | 236.81 Billion KRW | 21.41% |
| 2014 Q2 | 166.9 Billion KRW | 51.16% |
| 2014 Q1 | 110.41 Billion KRW | 13.81% |
| 2013 Q2 | 54.62 Billion KRW | 118.52% |
| 2013 Q3 | 63.49 Billion KRW | 16.24% |
| 2013 FY | 97.01 Billion KRW | -3.94% |
| 2013 Q4 | 97.01 Billion KRW | 52.8% |
| 2013 Q1 | 24.99 Billion KRW | -75.25% |
| 2012 Q1 | 98.33 Billion KRW | 0.0% |
| 2012 Q4 | 100.99 Billion KRW | 0.0% |
| 2012 FY | 100.99 Billion KRW | -12.92% |
| 2011 Q2 | 95.91 Billion KRW | -2.52% |
| 2011 FY | 115.98 Billion KRW | -0.9% |
| 2011 Q1 | 98.39 Billion KRW | 0.0% |
| 2011 Q3 | 52.02 Billion KRW | -45.76% |
| 2010 Q3 | 57.34 Billion KRW | -36.06% |
| 2010 Q1 | 198.24 Billion KRW | 0.0% |
| 2010 Q2 | 89.69 Billion KRW | -54.76% |
| 2010 FY | 117.03 Billion KRW | -48.62% |
| 2009 Q1 | 205.96 Billion KRW | 0.0% |
| 2009 Q2 | 223.53 Billion KRW | 8.53% |
| 2009 FY | 227.79 Billion KRW | 2.29% |
| 2009 Q3 | 206.99 Billion KRW | -7.4% |
| 2008 Q3 | 164.69 Billion KRW | 11.75% |
| 2008 Q1 | 136.96 Billion KRW | 0.0% |
| 2008 Q2 | 147.38 Billion KRW | 7.61% |
| 2008 FY | 222.7 Billion KRW | 30.7% |
| 2007 Q1 | 114.61 Billion KRW | 0.0% |
| 2007 Q2 | 130.72 Billion KRW | 14.05% |
| 2007 Q3 | 188.21 Billion KRW | 43.98% |
| 2007 FY | 170.39 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -6398.586% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | -84.005% |
| HANDOK Inc. | 283.45 Billion KRW | -101.803% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -2749.825% |
| Yuhan Corporation | -69.18 Billion KRW | 926.783% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | -194.932% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 15619.553% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | -10.453% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 1863.762% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -655.896% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -1452.831% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -593.19% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -2178.21% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -6398.586% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 457.855% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | -184.664% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -234.626% |
| JW Holdings Corporation | 480.68 Billion KRW | -19.001% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -247.559% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -486596.953% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -270.55% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -24227.708% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -2386.896% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | -226.921% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -1000.579% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -6398.586% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -261.36% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | -59.703% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -270.55% |
| Yuhan Corporation | -69.18 Billion KRW | 926.783% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -320.63% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -858.575% |
| Suheung Co., Ltd. | 429.14 Billion KRW | -33.293% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -270.55% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -392.119% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -3382.607% |
| CKD Bio Corp. | 143.29 Billion KRW | -299.188% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -392.838% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 2477.312% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 1378.716% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -24227.708% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | -35.281% |
| Boryung Corporation | 187.72 Billion KRW | -204.708% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 896.243% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -655.896% |
| JW Lifescience Corporation | 26.09 Billion KRW | -2092.436% |